Treace Medical Concepts, Inc. (TMCI) — Financial statements
Income statement, balance sheet, and cash flow for Treace Medical Concepts, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 213↑1.6% | 209↑11.9% | 187↑31.9% | 142↑50.2% | 94 | |
| Cost of Revenue | 43↑4.5% | 41↑16.8% | 35↑27.8% | 28↑63.0% | 17 | |
| Gross Profit | 170↑0.9% | 168↑10.7% | 152↑32.9% | 114↑47.4% | 78 | |
| Operating Expenses | ||||||
| R&D Expenses | 20↓1.5% | 21↑33.3% | 15↑13.7% | 14↑33.1% | 10 | |
| General & Administrative Expenses | 63↑12.6% | 56↑18.5% | 47↑42.5% | 33↑79.0% | 18 | |
| Selling & Marketing Expenses | 141↓4.6% | 148↑4.8% | 141↑34.7% | 105↑59.9% | 65 | |
| SG&A Expenses | 204↑0.1% | 203↑8.2% | 188↑36.6% | 138↑64.1% | 84 | |
| Other Expenses | 0.00 | 0.00 | 0.00↑100.0% | -2 | 0.00 | |
| Operating Expenses | 224↓0.0% | 224↑10.1% | 203↑36.3% | 149↑58.6% | 94 | |
| Total Costs & Expenses | 267↑0.7% | 265↑11.1% | 239↑35.0% | 177↑59.3% | 111 | |
| Operating Results | ||||||
| Operating Income | -54↑2.8% | -56↓8.3% | -51↓47.6% | -35↓111.0% | -17 | |
| Depreciation & Amortization | 11↑24.7% | 8↑57.3% | 5↑150.9% | 2↑211.4% | 0.69 | |
| EBITDA | -43↓2.6% | -42↓7.8% | -39↓7.5% | -36↓129.5% | -16 | |
| EBIT | -54↓6.3% | -50↓13.8% | -44↓15.5% | -38↓132.9% | -16 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↓571.0% | -0.38↓124.3% | 2↑150.5% | -3↑23.7% | -4 | |
| Interest Income | 3↓43.1% | 5↓27.5% | 7↑412.3% | 1↑7194.4% | 0.02 | |
| Interest Expense | 5↑1.2% | 5↑1.7% | 5↑17.5% | 4↑8.3% | 4 | |
| Non-Operating Income | -0.47↑90.9% | -5↑26.4% | -7↓297.8% | 4↑19950.0% | -0.02 | |
| Other Income / Expenses | -5↓8714.5% | -0.06↓102.9% | 2↑123.8% | -8↓97.2% | -4 | |
| Income Before Tax | -59↓5.8% | -56↓12.6% | -50↓15.7% | -43↓108.3% | -21 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -59↓5.8% | -56↓12.6% | -50↓15.7% | -43↓108.3% | -21 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -59↓5.8% | -56↓12.6% | -50↓15.7% | -43↓108.3% | -21 | |
| Bottom-Line Net Income | -59↓5.8% | -56↓12.6% | -50↓15.7% | -43↓106.4% | -21 | |
| EPS (Basic) | -0.93↓3.3% | -0.90↓11.1% | -0.81↓5.2% | -0.77↓102.6% | -0.38 | |
| EPS (Diluted) | -0.93↓3.3% | -0.90↓11.1% | -0.81↓5.2% | -0.77↓102.6% | -0.38 | |
| Weighted Average Shares | 63↑1.9% | 62↑2.1% | 61↑10.1% | 55↑2.0% | 54 | |
| Weighted Average Diluted Shares | 63↑1.9% | 62↑2.1% | 61↑10.1% | 55↑2.0% | 54 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.